Communiqués de presse Archive - Page 14 of 19 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011

OSE Immunotherapeutics Presentation at H.C. Wainwright BIOCONNECT 2021

OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2

OSE Immunotherapeutics Receives €5.2 M in Public Funding

OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 of FR104

OSE Immunotherapeutics to Present at SITC Annual Meeting And Additional Summits

OSE Immunotherapeutics Provides COVID-19 Vaccine Update on CoVepiT

OSE Immunotherapeutics Presents OSE-230

OSE Immunotherapeutics Announces Publication for Selective Antibody Antagonist BI765063

OSE Immunotherapeutics Receives European Patent Notice of Allowance for FR104

Précédent
1
…
11
12
13
14
15
16
17
…
19
Suivant